Skip to main content
Top
Published in: Internal and Emergency Medicine 7/2019

01-10-2019 | Acute Kidney Injury | IM - ORIGINAL

Comparison of incidence of acute kidney injury, chronic kidney disease and end-stage renal disease between atrial fibrillation and atrial flutter: real-world evidences from a propensity score-matched national cohort analysis

Authors: Wei-Syun Hu, Cheng-Li Lin

Published in: Internal and Emergency Medicine | Issue 7/2019

Login to get access

Abstract

We investigated the adverse renal outcomes in patients affected by either atrial fibrillation (Afib) or atrial flutter (AFL). Using the Taiwan National Health Insurance research database, both cohorts were 1:1 propensity score matched based on age, sex, index year, and comorbidity using logistic regression model. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) of acute kidney injury (AKI), chronic kidney disease (CKD), and end-stage renal disease (ESRD) between the two cohorts were obtained using Cox proportional hazard regression models. Competing-risks regression models were applied to calculate the subhazard ratios (SHRs) and corresponding 95% CIs of the adverse renal outcomes. Afib patients were 1.15 and 1.33 times more likely to experience CKD and ESRD, respectively, than AFL patients (incidence rate per 10,000 person-years (IR): CKD, 10.8 vs 9.41; ESRD, 4.44 vs 3.34), with the adjusted HRs of 1.18 and 1.32 (CKD, 95% CI = 1.07–1.30; ESRD, 95% CI = 1.12–1.55). Afib patients were 1.08 times (95% CI = 1.01–1.16) more likely to have AKI than AFL patients after adjusting for confounding covariates. Competing risk analysis showed that Afib patients were 1.08 (95% CI = 1.01–1.15), 1.18 (95% CI = 1.07–1.30) and 1.32 (95% CI = 1.12–1.55) times more likely to experience AKI, CKD and ESRD than AFL subjects. This study showed that Afib conferred worse renal events of AKI, CKD and ESRD than AFL.
Literature
1.
go back to reference January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, American College of Cardiology, American Heart Association Task Force on Practice Guidelines et al (2014) AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014(64):e1–e76CrossRef January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, American College of Cardiology, American Heart Association Task Force on Practice Guidelines et al (2014) AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014(64):e1–e76CrossRef
2.
go back to reference Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, ESC Committee for Practice Guidelines (CPG) et al (2012) focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation: developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012(33):2719–2747 Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, ESC Committee for Practice Guidelines (CPG) et al (2012) focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation: developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012(33):2719–2747
3.
go back to reference Page RL (2004) Clinical practice: newly diagnosed atrial fibrillation. N Engl J Med 351:2408–2416CrossRefPubMed Page RL (2004) Clinical practice: newly diagnosed atrial fibrillation. N Engl J Med 351:2408–2416CrossRefPubMed
4.
go back to reference Stewart S, Hart CL, Hole DJ, McMurray JJ (2002) A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 113:359–364CrossRefPubMed Stewart S, Hart CL, Hole DJ, McMurray JJ (2002) A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 113:359–364CrossRefPubMed
5.
go back to reference Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y (2009) Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 158(4):629–636CrossRefPubMed Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y (2009) Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 158(4):629–636CrossRefPubMed
6.
go back to reference Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS (2013) Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 127(5):569–574CrossRefPubMed Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS (2013) Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 127(5):569–574CrossRefPubMed
7.
go back to reference Nishimura M, Hsu JC (2018) Non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and end-stage renal disease. Am J Cardiol 121(1):131–140CrossRefPubMed Nishimura M, Hsu JC (2018) Non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and end-stage renal disease. Am J Cardiol 121(1):131–140CrossRefPubMed
8.
go back to reference Stamellou E, Floege J (2018) Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation. Nephrol Dial Transplant 33(10):1683–1689CrossRefPubMed Stamellou E, Floege J (2018) Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation. Nephrol Dial Transplant 33(10):1683–1689CrossRefPubMed
10.
go back to reference Hu WS, Lin CL (2019) Risk of new-onset atrial fibrillation among heart, kidney and liver transplant recipients: insights from a national cohort study. Intern Emerg Med 14(1):71–76CrossRefPubMed Hu WS, Lin CL (2019) Risk of new-onset atrial fibrillation among heart, kidney and liver transplant recipients: insights from a national cohort study. Intern Emerg Med 14(1):71–76CrossRefPubMed
11.
go back to reference Hu WS, Lin CL (2019) Comparison of CHA2DS2-VASc and AHEAD scores for the prediction of incident dementia in patients hospitalized for heart failure: a nationwide cohort study. Intern Emerg Med 14(3):395–402CrossRefPubMed Hu WS, Lin CL (2019) Comparison of CHA2DS2-VASc and AHEAD scores for the prediction of incident dementia in patients hospitalized for heart failure: a nationwide cohort study. Intern Emerg Med 14(3):395–402CrossRefPubMed
12.
go back to reference Fukunaga N, Takahashi N, Hagiwara S, Kume O, Fukui A, Teshima Y, Shinohara T, Nawata T, Hara M, Noguchi T, Saikawa T (2012) Establishment of a model of atrial fibrillation associated with chronic kidney disease in rats and the role of oxidative stress. Heart Rhythm 9(12):2023–2031CrossRefPubMed Fukunaga N, Takahashi N, Hagiwara S, Kume O, Fukui A, Teshima Y, Shinohara T, Nawata T, Hara M, Noguchi T, Saikawa T (2012) Establishment of a model of atrial fibrillation associated with chronic kidney disease in rats and the role of oxidative stress. Heart Rhythm 9(12):2023–2031CrossRefPubMed
13.
go back to reference Liao JN, Chao TF, Liu CJ, Wang KL, Chen SJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Chen SA (2015) Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int 87(6):1209–1215CrossRefPubMed Liao JN, Chao TF, Liu CJ, Wang KL, Chen SJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Chen SA (2015) Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int 87(6):1209–1215CrossRefPubMed
14.
go back to reference Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, Ojo A, Teal VL, Jensvold NG, Robinson NL, Dries DL, Bazzano L, Mohler ER, Wright JT, Feldman HI, Chronic Renal Insufficiency Cohort (CRIC) Study Group (2010) Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 159(6):1102–1107CrossRefPubMedPubMedCentral Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, Ojo A, Teal VL, Jensvold NG, Robinson NL, Dries DL, Bazzano L, Mohler ER, Wright JT, Feldman HI, Chronic Renal Insufficiency Cohort (CRIC) Study Group (2010) Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 159(6):1102–1107CrossRefPubMedPubMedCentral
15.
go back to reference Everett TH 4th, Olgin JE (2007) Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 4(3 Suppl):S24–S27CrossRefPubMed Everett TH 4th, Olgin JE (2007) Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 4(3 Suppl):S24–S27CrossRefPubMed
16.
go back to reference Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR (2001) C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104:2886–2891CrossRefPubMed Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR (2001) C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104:2886–2891CrossRefPubMed
17.
go back to reference Hatzinikolaou-Kotsakou E, Tziakas D, Hotidis A, Stakos D, Floros D, Papanas N, Chalikias G, Maltezos E, Hatseras DI (2006) Relation of c-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am J Cardiol 97:659–661CrossRefPubMed Hatzinikolaou-Kotsakou E, Tziakas D, Hotidis A, Stakos D, Floros D, Papanas N, Chalikias G, Maltezos E, Hatseras DI (2006) Relation of c-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am J Cardiol 97:659–661CrossRefPubMed
18.
go back to reference Dudley SC Jr, Hoch NE, McCann LA, Honeycutt C, Diamandopoulos L, Fukai T, Harrison DG, Dikalov SI, Langberg J (2005) Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the nadph and xanthine oxidases. Circulation 112:1266–1273CrossRefPubMed Dudley SC Jr, Hoch NE, McCann LA, Honeycutt C, Diamandopoulos L, Fukai T, Harrison DG, Dikalov SI, Langberg J (2005) Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the nadph and xanthine oxidases. Circulation 112:1266–1273CrossRefPubMed
19.
go back to reference Negi S, Sovari AA, Dudley SC (2010) Jr Atrial fibrillation: the emerging role of inflammation and oxidative stress. Cardiovasc Hematol Disord 10:262–268CrossRef Negi S, Sovari AA, Dudley SC (2010) Jr Atrial fibrillation: the emerging role of inflammation and oxidative stress. Cardiovasc Hematol Disord 10:262–268CrossRef
20.
go back to reference Burstein B, Qi XY, Yeh YH, Calderone A, Nattel S (2007) Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: a novel consideration in atrial remodeling. Cardiovasc Res 76(3):442–452CrossRefPubMed Burstein B, Qi XY, Yeh YH, Calderone A, Nattel S (2007) Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: a novel consideration in atrial remodeling. Cardiovasc Res 76(3):442–452CrossRefPubMed
Metadata
Title
Comparison of incidence of acute kidney injury, chronic kidney disease and end-stage renal disease between atrial fibrillation and atrial flutter: real-world evidences from a propensity score-matched national cohort analysis
Authors
Wei-Syun Hu
Cheng-Li Lin
Publication date
01-10-2019
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 7/2019
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-019-02089-1

Other articles of this Issue 7/2019

Internal and Emergency Medicine 7/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.